Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model

Spinel Karas,Ron H. J. Mathijssen,Ron H. N. van Schaik,Alan Forrest,Tim Wiltshire,Robert R. Bies,Federico Innocenti

DOI: https://doi.org/10.1002/cpt.3190

2024-02-12

Clinical Pharmacology & Therapeutics

Abstract:Neutropenia is the major dose‐limiting toxicity of irinotecan‐based therapy. The objective of this study was to assess whether inclusion of germline genetic variants into a population pharmacokinetic/pharmacodynamic model can improve prediction of irinotecan‐induced grade 4 neutropenia and identify novel variants of clinical value. A semimechanistic population pharmacokinetic/pharmacodynamic model was used to predict neutrophil response over time in 197 patients receiving irinotecan. Covariate analysis was performed for demographic/clinical factors and 4,781 genetic variants in 84 drug response‐ and toxicity‐related genes to identify covariates associated with neutrophil response. We evaluated the predictive value of the model for grade 4 neutropenia reflecting different clinical scenarios of available data on identified demographic/clinical covariates, baseline and post‐treatment absolute neutrophil counts (ANCs), individual pharmacokinetics, and germline genetic variation. Adding 8 genetic identified covariates (rs10929302 ( UGT1A1 ), rs1042482 ( DPYD ), rs2859101 ( HLA‐DQB3 ), rs61754806 ( NR3C1 ), rs9266271 ( HLA‐B ), rs7294 ( VKORC1 ), rs1051713 ( ALOX5 ), and ABCB1 rare variant burden) to a model using only baseline ANCs improved prediction of irinotecan‐induced grade 4 neutropenia from area under the receiver operating characteristic curve (AUC‐ROC) of 50–64% (95% confidence interval (CI), 54–74%). Individual pharmacokinetics further improved the prediction to 74% (95% CI, 64–84%). When weekly ANC was available, the identified covariates and individual pharmacokinetics yielded no additional contribution to the prediction. The model including only ANCs at baseline and at week 1 achieved an AUC‐ROC of 78% (95% CI, 69–88%). Germline DNA genetic variants may contribute to the prediction of irinotecan‐induced grade 4 neutropenia when incorporated into a population pharmacokinetic/pharmacodynamic model. This approach is generalizable to drugs that induce neutropenia and ultimately allows for personalized intervention to enhance patient safety.

pharmacology & pharmacy